Publications by authors named "M Carreras"

Purpose: To evaluate the clinical and patient-reported outcomes (PROMs) of cataract surgery with implantation of a wavefront-shaping extended depth of focus (EDOF) intraocular lens (IOL) in eyes with previous laser in situ keratomileusis (LASIK) for myopia correction.

Methods: This prospective observational study enrolled 50 eyes with previous LASIK from 25 patients (age: 46 to 70 years) who underwent cataract surgery with implantation of the AcrySof IQ Vivity IOL (Alcon Laboratories, Inc). Visual and refractive outcomes were evaluated during a 3-month follow-up.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs) have emerged as an integral component of the management of various cancers and have contributed to significant improvements in overall survival. Most available ICIs target anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4), and anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD1/PDL1). Gastrointestinal immune-related adverse events remain a common complication of ICIs.

View Article and Find Full Text PDF

The progressive incorporation of quality of life indicators in health planning meets a critical need: The evaluation of the performance of health services, which are under stress by multiple causes, but in particular by an ageing population. In general, national health plans rely on health expectancies obtained using the Sullivan method. The Sullivan health expectancy index combines age-specific mortality rates and age-specific prevalence of healthy life, obtained from health surveys.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed 10 years of data on adult patients with solid tumors enrolled in clinical trials, focusing on the clinical characteristics and the financial impact of sponsor contributions to drug costs.
  • Over the decade, the number of clinical trials increased significantly from 140 in 2010 to 459 in 2019, with a shift in drug use from mainly targeted therapies to a greater emphasis on immunotherapy.
  • The analysis showed that while the overall expenditure on antineoplastic drugs outside clinical trials was over EUR 120 million, sponsor contributions in trial settings amounted to about EUR 107 million, resulting in a potential cost avoidance of around EUR 92 million.
View Article and Find Full Text PDF